Wholomics @ ASCO Annual Meeting 2024

We are excited to share that Wholomics recently presented a significant blinded validation study at the ASCO Annual Meeting, the world’s largest cancer conference, which hosted over 40,000 oncologists, researchers, and key opinion leaders. This event was an incredible opportunity for us to make valuable connections and showcase our groundbreaking work in early cancer detection.

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at advanced stages, leading to increased mortality rates. The need for effective early detection methods is urgent, as early detection is critical for improving survival rates. To address this, we developed a proprietary early detection assay that leverages molecular signatures found in the blood. This study further validated the efficacy of our approach through a comprehensive blinded validation study.

Our research involved a retrospective analysis of serum samples from multiple biobanks. The study included control subjects, patients with chronic pancreatitis, and patients with PDAC. Using our proprietary technology, we quantitatively analyzed serum samples to identify disease-specific molecular signatures and develop a computational biomarker specific to PDAC.

Our technology demonstrated impressive accuracy in distinguishing PDAC patients from non-cancer controls in both the training and blinded validation cohorts, highlighting the robustness and potential of our blood-based test for early PDAC detection.

In addition to our focus on pancreatic cancer, we are actively working to apply our technology to other types of cancer, and the results are promising. Our goal is to revolutionize the early cancer detection market, making early diagnosis a reality for various cancer types and ultimately improving patient outcomes across the board.

The findings from this study indicate that utilizing disease-specific molecular markers in peripheral blood offers a highly accurate method for differentiating PDAC patients from healthy subjects and those with pre-cancerous diseases. If future studies validate these results across broader cohorts, our testing approach could be considered a viable screening mechanism for PDAC, aiming to facilitate early detection and improve patient outcomes.

We invite investors and physicians to learn more about our innovative approach to cancer diagnostics. By partnering with us, you can join a transformative journey toward early cancer detection and better patient care.

For more detailed information, please refer to our abstract.

Stay tuned for further updates as we continue to advance our mission to lead a global revolution in cancer care.